BioCentury
ARTICLE | Company News

HHS awards $12.1M to BioCryst for Ebola treatment

April 1, 2015 1:34 AM UTC

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) gained $0.45 to $9.02 after the Biomedical Advanced Research and Development Authority (BARDA) of HHS's Office of the Assistant Secretary for Preparedness and Response (ASPR) awarded the company a $12.1 million contract to develop and manufacture Ebola treatment BCX4430.

ASPR has the option to provide an additional $22.9 million under the contract. ...